A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
Phase of Trial: Phase III
Latest Information Update: 30 Jul 2018
Price : $35 *
At a glance
- Drugs Mercaptamine bitartrate (Primary)
- Indications Nephropathic cystinosis
- Focus Adverse reactions
- Sponsors Horizon Pharma; Raptor Pharmaceutical Inc
- 17 Jul 2017 Status changed from active, no longer recruiting to completed.
- 10 Feb 2017 Planned End Date changed from 1 Dec 2018 to 1 Jun 2017.
- 10 Feb 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2017.